Business UpdateJun 11, 2026, 04:16 PM
Zenas BioPharma to Present at H.C. Wainwright Neuro Summit
AI Summary
Zenas BioPharma, a clinical-stage biopharmaceutical company specializing in autoimmune diseases, announced that its management will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The presentation will be available on-demand starting June 15, 2026, at 7:00 a.m. ET, with a webcast and replay accessible on the company's investor relations website. Zenas is currently advancing late-stage molecules obexelimab and orelabrutinib, alongside earlier stage programs ZB021, ZB022, and ZB014.
Key Highlights
- Zenas BioPharma management will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
- The presentation will be available on-demand starting Monday, June 15, 2026, at 7:00 a.m. ET.
- A webcast and archived replay can be accessed on the Zenas BioPharma website under "Events and Presentations".
- Zenas is a clinical-stage global biopharmaceutical company focused on transformative therapies for autoimmune diseases.
- The company is advancing two late-stage molecules: obexelimab and orelabrutinib.
- Earlier stage programs include ZB021, ZB022, and ZB014.
Price Impact
More from ZBIO